Hb (g/L) | No. of patients | Median Hb (g/L) | Hb range (g/L) |
---|---|---|---|
Pre-treatment Hb | 128 | 86–169 | |
> 120 g/L | 69 | 136 | 122–169 |
≤ 120 g/L | 31 | 107 | 86–120 |
Mean on-treatment Hb | 127 | 96–157 | |
>120 g/L | 67 | 134 | 121–157 |
≤ 120 g/L | 33 | 113 | 96–119 |
End-of-treatment Hb | 121 | 77–159 | |
> 120 g/L | 46 | 134 | 121–159 |
≤ 120 g/L | 54 | 114 | 77–120 |
Toxicity | Grade | |||||||
---|---|---|---|---|---|---|---|---|
0 | 1 | 2 | 3 | 4 | ||||
Stomatitis | 68 | 12 | 10 | 9 | 1 | |||
Nausea, vomiting | 79 | 9 | 9 | 3 | 0 | |||
Diarrhoea | 57 | 17 | 12 | 13 | 1 | |||
Hand-foot syndrome Only in patients treated with capecitabine | 22 | 0 | 1 | 2 | 0 | |||
Radiodermatitis | 10 | 12 | 13 | 64 | 1 | |||
Infection | 51 | 14 | 23 | 9 | 3 | |||
Leucocyte count | 37 | 31 | 20 | 10 | 2 | |||
Haemoglobin level | 43 | 44 | 11 | 2 | 0 | |||
Platelet count | 58 | 36 | 3 | 3 | 0 |
Characteristics | n | LRC | DFS | DSS | OS |
---|---|---|---|---|---|
Pre-treatment Hb | |||||
79% | 77% | 85% | 73% | ||
> 120 g/L | 69 | ||||
57% | 57% | 56% | 39% | ||
≤ 120 g/L | 31 | ||||
Mean on-treatment Hb | |||||
78% | 76% | 82% | 68% | ||
> 120 g/L | 67 | ||||
60% | 60% | 67% | 50% | ||
≤ 120 g/L | 33 | ||||
End-of-treatment Hb | |||||
82% | 80% | 89% | 75% | ||
> 120 g/L | 46 | ||||
63% | 63% | 65% | 49% | ||
≤ 120 g/L | 54 | ||||
Performance status | |||||
73% | 73% | 80% | 72% | ||
PS 0 | 76 | ||||
69% | 64% | 66% | 34% | ||
PS 1–3 | 24 | ||||
P = 0.480 | P = 0.283 | P = 0.231 | |||
Tumour stage | |||||
75% | 75% | 84% | 68% | ||
T1–3 | 86 | ||||
50% | 44% | 38% | 25% | ||
T4 | 14 | ||||
Lymph node involvement | |||||
no | 65 | 79% | 79% | 87% | 70% |
yes | 35 | 59% | 56% | 60% | 48% |
Overall disease stage | |||||
79% | 79% | 87% | 70% | ||
I / II | |||||
64 | |||||
IIIA / IIIB | 59% | 57% | 61% | 49% | |
36 | |||||
Histologic tumour type | |||||
basaloid | 12 | 100% | 100% | 100% | 100% |
squamous | 88 | 68% | 67% | 74% | 57% |
P = 0.051 | |||||
Tumour site | |||||
69% | 68% | 78% | 62% | ||
anal canal | 72 | ||||
81% | 81% | 73% | 61% | ||
anal margin | 28 | ||||
Blood transfusion | |||||
no | 72% | 71% | 78% | 64% | |
91 | |||||
yes | 0% | 0% | 0% | 0% | |
9 | |||||
P = 0.950 | P = 0.333 | ||||
Overall radiation time | |||||
89% | 89% | 93% | 83% | ||
≤ 1,08 months | 29 | ||||
64% | 63% | 69% | 51% | ||
> 1,08 months | 71 | ||||
Operation | |||||
no | 73 | 89% | 88% | 88% | 69% |
yes | 27 | 29% | 29% | 52% | 45% |
Characteristics | No. of patients | ||||
---|---|---|---|---|---|
Gender | |||||
female | 60 | ||||
male | 40 | ||||
Mean age (range) | 63 (34–87) | ||||
Performance status (WHO) | |||||
0 | 76 | ||||
1 | 20 | ||||
2 | 3 | ||||
3 | 1 | ||||
Tumour type | |||||
Carcinoma of the anal canal | 72 | ||||
Carcinoma of the anal margin | 28 | ||||
Tumour histology | |||||
Basaloid | 12 | ||||
Squamous | 88 | ||||
TNM | N0 | N1 | N2 | N3 | |
T1 | 9 | 0 | 1 | 0 | |
T2 | 36 | 6 | 1 | 0 | |
T3 | 19 | 10 | 3 | 1 | |
T4 | 1 | 1 | 7 | 5 | |
Tumour stage | |||||
I | 9 | ||||
II | 55 | ||||
IIIA | 17 | ||||
IIIB | 19 |